Tag: EU AI Act

AI drug discovery in 2026: between promise and production

BCG counted 73 AI-derived molecules in clinical pipelines, but success rates collapse from 80-90% in Phase I to around 40% in Phase II. Insilico Medicine's rentosertib is the first entirely AI-designed molecule to show an efficacy signal in Phase IIa, published in Nature Medicine in June 2025. An honest 2026 map: what works, what doesn't, what is changing in Europe.